Wells Fargo Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Tandem Diabetes Care (TNDM) and raises the price target from $45 to $50.
May 03, 2024 | 6:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Tandem Diabetes Care and raises the price target from $45 to $50.
The increase in price target by a reputable analyst like Larry Biegelsen suggests a positive outlook on TNDM's financial performance and market position. This endorsement is likely to instill confidence among investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100